Barbara Hildebrandt

7.3k total citations · 2 hit papers
115 papers, 4.1k citations indexed

About

Barbara Hildebrandt is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Barbara Hildebrandt has authored 115 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Hematology, 38 papers in Molecular Biology and 34 papers in Genetics. Recurrent topics in Barbara Hildebrandt's work include Acute Myeloid Leukemia Research (73 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (21 papers) and Histone Deacetylase Inhibitors Research (15 papers). Barbara Hildebrandt is often cited by papers focused on Acute Myeloid Leukemia Research (73 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (21 papers) and Histone Deacetylase Inhibitors Research (15 papers). Barbara Hildebrandt collaborates with scholars based in Germany, Austria and United States. Barbara Hildebrandt's co-authors include Ulrich Germing, Carlo Aul, Aristoteles Giagounidis, Corinna Strupp, Rainer Haas, Andrea Kuendgen, Norbert Gattermann, Sabine Knipp, Ulrich Germing and Christian Steidl and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Barbara Hildebrandt

109 papers receiving 4.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes

2007 695 citations Luca Malcovati, Ulrich Germing et al. Journal of Clinical Oncology profile →
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

2007 540 citations Detlef Haase, Ulrich Germing et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara Hildebrandt Germany	29	3.1k	1.5k	1.4k	449	444	115	4.1k
Yogen Saunthararajah United States	38	2.8k 0.9×	2.7k 1.8×	1.4k 1.0×	316 0.7×	584 1.3×	164	5.1k
Manuel Aivado United States	31	2.1k 0.7×	1.2k 0.8×	843 0.6×	186 0.4×	508 1.1×	89	3.3k
Siddhartha Jaiswal United States	24	2.8k 0.9×	2.1k 1.4×	1.6k 1.1×	240 0.5×	1.4k 3.1×	54	6.9k
Claudia D. Baldus Germany	36	3.2k 1.0×	2.3k 1.6×	1.0k 0.7×	1.3k 2.9×	487 1.1×	124	4.6k
Anwar N. Mohamed United States	21	1.5k 0.5×	1.0k 0.7×	636 0.4×	600 1.3×	531 1.2×	70	2.7k
Mathijs A. Sanders Netherlands	29	1.6k 0.5×	1.9k 1.3×	572 0.4×	301 0.7×	374 0.8×	75	3.3k
Klaus H. Metzeler Germany	29	2.6k 0.8×	2.3k 1.5×	825 0.6×	478 1.1×	1.0k 2.3×	115	4.3k
Rashmi Kanagal‐Shamanna United States	34	1.9k 0.6×	1.2k 0.8×	1.3k 0.9×	477 1.1×	817 1.8×	223	4.0k
Robert Månsson Sweden	34	2.2k 0.7×	2.6k 1.7×	759 0.5×	408 0.9×	623 1.4×	73	5.6k
Bert A. van der Reijden Netherlands	29	1.8k 0.6×	2.5k 1.6×	634 0.4×	337 0.8×	485 1.1×	93	3.7k

Countries citing papers authored by Barbara Hildebrandt

Since Specialization

Citations

This map shows the geographic impact of Barbara Hildebrandt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Hildebrandt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Hildebrandt more than expected).

Fields of papers citing papers by Barbara Hildebrandt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Hildebrandt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Hildebrandt. The network helps show where Barbara Hildebrandt may publish in the future.

Co-authorship network of co-authors of Barbara Hildebrandt

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Hildebrandt. A scholar is included among the top collaborators of Barbara Hildebrandt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Hildebrandt. Barbara Hildebrandt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ramachandran, Haribaskar, Alexander Becker, Jochen Dobner, et al.. (2025). CRISPR/Cas9-mediated editing of MIC13 in human induced pluripotent stem cells: A model for mitochondrial hepato-encephalopathy. Stem Cell Research. 89. 103870–103870.

Nachtkamp, Kathrin, Franz Schulz, Aldona Kasprzak, et al.. (2025). Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS). Annals of Hematology. 104(6). 3251–3259.

Ramachandran, Haribaskar, et al.. (2024). Prime-Editing of human ACTB in induced pluripotent stem cells to model human ACTB Loss-of-Function diseases and compensatory mechanisms. Stem Cell Research. 75. 103304–103304. 4 indexed citations

Hildebrandt, Barbara, Guido Kobbe, Norbert Gattermann, et al.. (2022). Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis. Annals of Hematology. 101(5). 1031–1038. 1 indexed citations

Hildebrandt, Barbara, et al.. (2021). Generation of an induced pluripotent stem cell line (IUFi001) from a Cockayne syndrome patient carrying a mutation in the ERCC6 gene. Stem Cell Research. 55. 102456–102456. 3 indexed citations

Kaivers, Jennifer, Jürgen Peters, Christina Rautenberg, et al.. (2021). The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T. Leukemia Research. 112. 106757–106757. 3 indexed citations

Kuendgen, Andrea, Catharina Müller‐Thomas, Michael Lauseker, et al.. (2018). Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature. Oncotarget. 9(45). 27882–27894. 54 indexed citations

Nachtkamp, Kathrin, Corinna Strupp, Andrea Kündgen, et al.. (2016). Causes of death in 2877 patients with myelodysplastic syndromes. Annals of Hematology. 95(6). 937–944. 63 indexed citations

Kuendgen, A., Catharina Müller‐Thomas, Michael Lauseker, et al.. (2013). Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine. Blood. 122(21). 2757–2757. 2 indexed citations

10.

Kuendgen, Andrea, Michael Lauseker, Torsten Haferlach, et al.. (2013). Prognostic Impact Of Molecular Mutations In 182 Patients With Myelodysplastic Syndromes. Blood. 122(21). 2758–2758. 3 indexed citations

11.

Kuendgen, A., Gesine Bug, Oliver G. Ottmann, et al.. (2011). Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Clinical Epigenetics. 2(2). 389–399. 29 indexed citations

12.

Eckstein, Niels, Kati Servan, Barbara Hildebrandt, et al.. (2009). Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells. Cancer Research. 69(7). 2996–3003. 134 indexed citations

13.

Stracke, Christian M. & Barbara Hildebrandt. (2007). Quality Development and Quality Standards in e Learning: Adoption, Implementation, and Adaptation. EdMedia: World Conference on Educational Media and Technology. 2007(1). 4158–4165. 12 indexed citations

14.

Braunstein, S.E., P. Reinecke, Rainer Haas, et al.. (2007). P112 Prognostic impact of bone marrow fibrosis in myelodysplastic syndromes (MDS). Leukemia Research. 31. S100–S100. 1 indexed citations

15.

Malcovati, Luca, Ulrich Germing, Andrea Kuendgen, et al.. (2007). Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. Journal of Clinical Oncology. 25(23). 3503–3510. 695 indexed citations breakdown →

16.

Hildebrandt, Barbara, Christian M. Stracke, & Michal Jacovi. (2006). Support Systems for Quality in E-Learning. EdMedia: World Conference on Educational Media and Technology. 2006(1). 151–158. 4 indexed citations

17.

Kuendgen, Andrea, Mathias Schmid, Richard F. Schlenk, et al.. (2005). The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia. Cancer. 106(1). 112–119. 188 indexed citations

18.

Haase, Dagmar, Christian Steidl, Julie Schanz, et al.. (2005). Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS.. Blood. 106(11). 787–787. 10 indexed citations

19.

Knipp, Sabine, Barbara Hildebrandt, Aristoteles Giagounidis, et al.. (2004). Intensive Chemotherapy Is Not Recommended for Patients with AML or High-Risk MDS Aged over 60 Years with Complex Karyotype Anomalies.. Blood. 104(11). 72–72. 6 indexed citations

20.

Hildebrandt, Barbara, et al.. (2004). Jak podnieść jakość w e-learningu? European Quality Observatory. 76–81. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact